Ayahuasca vs Psilocybin

The chemistry actually matters

Both compounds work primarily through serotonin 5-HT2A receptor agonism, which is what makes them "classical" psychedelics. But the route, kinetics, and accompanying compounds produce noticeably different experiences.

Ayahuasca's DMT is only orally active because the β-carbolines in Banisteriopsis caapi inhibit the monoamine oxidase enzymes that would otherwise break DMT down in the gut. Those same MAO inhibitors are independently psychoactive, mildly antidepressant, and responsible for both the slower onset and the dietary restrictions ayahuasca requires. The β-carbolines also account for much of the physical body load — including the purging.

Psilocybin is taken orally, converted to psilocin in the body, and acts more directly without an additional pharmacological layer. The experience tends to be reported as smoother on the body, more visually rich, and somewhat more flexible in tone — capable of being deeply therapeutic, contemplative, or even playful depending on set and setting.

Clinical evidence

Psilocybin's clinical evidence base is larger, more recent, and more rigorous. Multiple randomised controlled trials have been published in top-tier journals (NEJM, Nature Medicine, JAMA Psychiatry) for treatment-resistant depression, major depressive disorder, alcohol use disorder, and end-of-life anxiety. The FDA has granted Breakthrough Therapy designation twice. Phase III trials are ongoing.

Ayahuasca's clinical evidence is meaningful but smaller. A Brazilian RCT showed strong antidepressant effects from a single session in treatment-resistant depression. Observational data suggests benefits for substance use disorders. Long-term naturalistic studies of ritual users show no cognitive decline and possibly some neuroprotective effects. But the research base is roughly 5–10 years behind psilocybin's.

The retreat experience differs more than the chemistry does

Ayahuasca, almost without exception, is encountered in a multi-night group retreat with Amazonian-lineage ceremonial framing, live music (icaros), and a maestro or maestra leading. The container is communal, the framework is explicitly spiritual or shamanic, and integration happens partly through the group.

Psilocybin retreats vary much more widely in format. They can look like an ayahuasca-style ceremony (especially in Oaxaca and at Mazatec-lineage centres), or they can look like clinical settings with on-site physicians and one-on-one therapy. Mexico has both.

Which fits which question

This is not a rule, but a useful generalisation:

• If you're working with treatment-resistant depression or have specific psychiatric goals, the clinical evidence currently favours psilocybin, and clinically-supervised settings exist in Mexico that don't exist for ayahuasca.
• If you're seeking deep, sustained, group-held emotional work with strong physical-body involvement, ayahuasca's traditional format is purpose-built for that.
• If your body is fragile or you have multiple medications in play, psilocybin's cleaner pharmacology is generally safer to navigate. Ayahuasca's MAO interactions create real risk.
• If you want a single intense experience rather than a multi-night container, psilocybin fits that shape. Most ayahuasca offerings are explicitly built around multiple ceremonies.

What both share

Both require honest screening — for psychiatric history, cardiovascular health, and medications. Both demand integration support to translate experience into change. Neither is a one-shot fix. Both can be remarkable. Both can be destabilising. The provider matters more than the medicine.

Last updated May 2026.